5 Top Gainers In Healthcare Sector (ATOS, AZRX, NSTG...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Atossa Genetics Inc. (ATOS)

Gained 30.08% to close Wednesday's (Jan.9) trading at $1.60.

News: The Company announced successful completion and final results from its phase I dose-escalation study of topical Endoxifen in healthy male subjects.

The topical Endoxifen is being developed to treat or prevent several health conditions in both men and women. For men, topical Endoxifen is being developed to prevent and treat gynecomastia, a condition which refers to male breast enlargement and accompanying pain. For women, topical Endoxifen is being developed to treat mammographic breast density or MBD.

Near-term Catalyst:

-- A phase II study of topical Endoxifen in women with mammographic breast density (MBD) is underway, with study completion expected in the second quarter 2019.

2. SELLAS Life Sciences Group Inc. (SLS)

Gained 24.81% to close Wednesday's trading at $1.66.

News: The Company provided a corporate update on the clinical development of Galinpepimut-S (GPS) and Nelipepimut-S (NPS), which are both in late-stage development.

A phase III registrational study for Galinpepimut-S in acute myeloid leukemia is expected to be initiated in the second quarter of 2019.

Enrollment of phase I/II Basket Trial of GPS plus Keytruda in patients with hematologic malignancies and solid tumors has been initiated, with interim analysis expected in Q4, 2019.

SELLAS is currently in continuing active discussions with the FDA regarding the optimal development path for Nelipepimut-S in triple negative breast cancer, including the potential for accelerated approval; a registration-enabling phase III trial design and biostatistical plan; and the potential for breakthrough designation.

3. AzurRx BioPharma Inc. (AZRX)

Gained 24.81% to close Wednesday's trading at $1.66.

News: No news

Recent events:

On December 19, 2018, the Company announced the initiation of a phase II study of MS1819-SD in cystic fibrosis patients with exocrine pancreatic insufficiency, dubbed OPTION. Initial top-line data from this trial is expected in 2019.

Last September, the Company successfully completed a phase IIa study of MS1819-SD for the treatment of exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis, which demonstrated both safety and statistically significant efficacy.

4. NeoGenomics Inc. (NEO)

Gained 13.84% to close Wednesday's trading at $14.97.

News: The Company is all set to join the S&P SmallCap 600, effective prior to the open of trading on Monday, January 14, 2019.

Near-term Catalyst:

The Company is expected to report its fourth quarter and fiscal year 2018 financial results in the last week of February.

For 2018, the Company has forecast consolidated revenue in the range of $270 million to $272 million, and adjusted EPS in the range of $0.17 to $0.19.

5. NanoString Technologies Inc. (NSTG)

NanoString Technologies provides life science tools for translational research and molecular diagnostic products.

Gained 13.23% to close Wednesday's trading at $20.29.

News: No news

Recent event:

On January 6, the Company provided preliminary operational and financial results for the fourth quarter and fiscal year ended December 31, 2018, which came in above its prior forecast.

Total revenue for the fourth quarter of 2018 is expected to be approximately $30 million versus prior guidance of $28 to $29 million. Total revenue for the fiscal year 2018 is expected to be in the range of $106 to $107 million, versus prior guidance of $104 to $106 million.